Breaking Finance News

Numis announced Alliance Pharma PLC (LON:APH), boosting its stock price target to 71.00GBX today

In a report released on Monday December 04, 2017 Numis increased the stock price target of Alliance Pharma PLC (LON:APH) to 71.00GBX reporting a possible upside of 0.17%.

Previously on 12/01/2017, Numis released a statement about Alliance Pharma PLC (LON:APH) increased the target price from 0.00GBX to 66.00GBX. At the time, this indicated a possible upside of 0.13%.

Just yesterday Alliance Pharma PLC (LON:APH) traded 0.48% higher at 60.63GBX. Alliance Pharma PLC’s 50-day moving average is 52.79GBX and its 200-day moving average is 50.55GBX. The last stock price is up 3.85% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.01% over the same time period. 472,395 shares of APH traded hands, down from an average trading volume of 835,652

Recent Performance Chart

Alliance Pharma PLC (LON:APH)

Alliance Pharma PLC has 52 week low of 41.33GBX and a 52 week high of 57.50GBX with a PE ratio of 13.82 and has a market capitalization of 0 GBX.

In addition to Numis reporting its stock price target, a total of 1 brokerage has issued a ratings update on the company. The average stock price target is 60.00GBX with 1 brokerage rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Alliance Pharma PLC (LON:APH)

Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international. The Company's therapeutic areas of focus include cardiovascular, central nervous system, child health, consumer health, dermatology, endocrinology, gastroenterology, obstetrics and gynecology, oral health, oncology, stoma care, toxicology and travel health. The Company's product categories include prescription only medicines, over the counter medications, medical devices, cosmetics and nutritional supplements. The Company's products include SkinSafe, Lift Plus, AbsorbaGel, DeoGel, LaVera, ClearWay, Gelclair, ImmuCyst 81mg, Hydromol, MacuShield, Lypsyl, Anbesol Adult Strength Gel, MolluDab and Ashton & Parsons Infants' Powders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.